Evidence map›Paper›PMID 40810287›Full record

ArticlemAbs2025

CDR clipping-induced heterodimerization: identification of a novel dimerization mechanism in a co-formulated antibody cocktail via a multifaceted mass spectrometry approach.

Andrew J Heindel, Yang Shen, Timothy N Tiambeng, Yuetian Yan, Shunhai Wang, Ning Li

Abstract read
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrew J HeindelAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Yang ShenAntibody Engineering, Regeneron PharmaceuticalsInc, Inc., Tarrytown, NY, USA.
Timothy N TiambengAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Yuetian YanAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.ORCID 0000-0001-9032-7880
Shunhai WangAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.ORCID 0000-0003-4055-2187
Ning LiAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Co-formulated antibody cocktails are becoming an increasingly popular therapeutic class; however, they present analytical challenges over traditional single monoclonal antibody (mAb) formulations. One paramount concern is the formation of heteromeric species that have unknown impacts on safety and efficacy. Consequently, effective approaches for identifying and characterizing high-molecular weight (HMW) impurities are critical to the successful development of this therapeutic class. In this study, we used a multifaceted mass spectrometry approach to characterize a unique dimer species formed between two co-formulated mAbs under thermal stress, revealing an intriguing dimerization mechanism that is driven by complementarity-determining region clipping-induced domain swap. Size exclusion chromatography-mass spectrometry, complemented by post-column denaturation, was utilized at both intact and subunit levels to pinpoint the dimerization interface. Additionally, by probing the disulfide bond susceptibility changes via limited reduction and middle-down analysis, the structural changes of the involved domains were studied. These results highlight the critical role of sophisticated analytical methods in comprehending and addressing the complexities linked to co-formulated mAb cocktails.

Indexed as

Antibodies, MonoclonalComplementarity Determining RegionsProtein MultimerizationAnimalsCombined Antibody TherapeuticsHumansMass SpectrometryAntibodies, MonoclonalCombined Antibody TherapeuticsComplementarity Determining Regionsdomain swappingFixed dose combinationheterodimermiddle-downmonoclonal antibodynative LC-MSpost-column denaturationSEC-PCD-MStherapeutic antibody

Identifiers

PMID40810287
PMCPMC12355704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.